CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: September 7, 2018
Result type: Reports
Project Number: SR0435-000
Product Line: Reimbursement Review

Generic Name: Tolvaptan

Brand Name: Jinarc

Manufacturer: Otsuka Canada Pharmaceutical Inc.

Therapeutic Area: Autosomal dominant polycystic kidney disease

Indications: Autosomal dominant polycystic kidney disease (ADPKD)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 24, 2016

Recommendation Type: Do not list